|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide, KLH conjugated, corresponding to to the 2nd extracellular domain of human G Protein-Coupled Receptor GPR105.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.7|
|Contains||0.01% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100 to 1:200|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
OPA1-15556 detects GPR105 from human samples.
OPA1-15556 has been successfully used in immunohistochemistry procedures. By immunohistochemistry, OPA1-15556 detects GPR105 in formalin fixed, paraffin embedded human tissues.
The OPA1-15556 immunogen is a synthetic peptide, KLH conjugated, corresponding to to the 2nd extracellular domain of human G Protein-Coupled Receptor GPR105.
GPR105 has been reported to be expressed in brain. ESTs have been isolated from kidney, placenta, uterus, and heart/melanocyte/uterus libraries.
G-protein Coupled Receptors (GPCRs) comprise one of the largest families of signaling molecules with more than a thousand members currently predicted to exist. All GPCRs share a structural motif consisting of seven membrane-spanning helices, and exist in both active and inactive forms. An array of activating ligands participate in the conformation of GPCRs which leads to signaling via G-proteins and downstream effectors. Ongoing studies have also shown the vast series of reactions which participate in the negative regulation of GPCRs. This "turn-off" activity has tremendous implications for the physiological action of the cell, and continues to drive pharmacological research for new drug candidates. Two blockbuster drugs which have been developed as GPCR-targeted pharmaceuticals are Zyprexa (Eli Lilly) and Claritin (Schering-Plough) which have multi-billion dollar shares of the mental health and allergy markets, respectively.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.